Clinical Trial Update: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SAIT101 to Rituximab as first-line immunotherapy in low tumor burden follicular lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• SAIT101

Snippet

Sponsor: Archigen Biotech Limited | Conditions: Lymphoma, Follicular | Phase 3 | Status: COMPLETED | Results posted: 2020-10-08